Options Data for US Stocks: End-of-Day and Historical Learn more

Try our APIs with free plan!

I-MAB SPONS.ADS/1 -0001 Financial Data Overview

Price chart is built with Anychart

NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which is in Phase 2b clinical trail for Wet AMD and other retinal diseases; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. The company has a strategic licensing agreement with AffaMed and AskGene to develop and commercialize VIS-101 to Visara. It also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Prev. Close 1.741
Open 1.741
High 1.741
Low 1.741
52 wk Range 0.77-5.6
Market Cap 202 M
Shares Outstanding 116 M
Revenue 569 K
Beta 1.561

* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.


Why to choose EODHD?

Prices start at $19.99

24/7 Live support

Robust, powerful and reliable data

API Simplicity of a few lines of code


Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW

Get I-MAB SPONS.ADS/1 -0001 data using free add-ons & libraries


Get I-MAB SPONS.ADS/1 -0001 Fundamental Data

I-MAB SPONS.ADS/1 -0001 Fundamental data includes:

  • Net Revenue: 569 K
  • EBITDA: -94 201 000
  • Earnings Per Share:
  • Income Statements
  • Balance Sheets
  • Cash flows

Plans with Fundamental data

Starting from

$ 59.99 /mo.
COMPARE PLANS

End-of-day & Earnings data

Get I-MAB SPONS.ADS/1 -0001 Earnings data

Corporate Events Calendar & News package for

$ 19.99 /mo.

What’s included:

  • Latest Release: 2026-05-14
  • EPS/Forecast: -0.23
GET THE PACKAGE

Get I-MAB SPONS.ADS/1 -0001 End-of-day data

EOD Historical Data package for

$ 19.99 /mo.

What’s included:

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends
GET THE PACKAGE
Try our APIs
with free plan!

Or get access to advanced financial data starting only $19.99

TRY NOW
  • Flexibility: No long-term commitments, just a minimum of one month
  • Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.

What’s included:

  • API Calls per Day: 100 000/day
  • API Requests per Min.: 1000/minute
  • Type of Usage: Personal use

Data access:

Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.

GET THE PACKAGE
Live chat support

Send the request

Leave your email and our team will contact you ASAP.